Contribute Try STAT+ Today

Patients and patient advocacy groups are demanding faster approval for treatments they and their constituents need, and need right now. Groups more generally interested in reducing government control over drug approval are accompanying them in this mission. The target? The US Food and Drug Administration.

Getting the FDA to approve drugs faster is seen as one way to get the access that many patients and their families want. Vice President Pence and many other legislators seem to have been persuaded that the FDA is the roadblock. It isn’t. The real barrier is payers of prescription drug benefits, such as health insurance companies and self-insured employers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The FDA of 2009 – 2014 absolutely was obstructing accelerated approvals. The uproar from patients was justified and worked. Now the FDA is more flexible and listening to patients . But PHRMA is not. They gutted the Adrea Sloan Compassionate Use Reform Act. We patients don’t believe the companies , even the small ones , cannot afford more compassionate use. They are our next focus . If they think their drugs are good enough for accelerated approval then they are good enough for compassionate access. We hold them morally responsible . All this potential access precedes the payers . We will deal with them as they try to put a price on human life.

Comments are closed.